Individualised screening for diabetic retinopathy: the ISDR study - rationale, design and methodology for a randomised controlled trial comparing annual and individualised risk-based variable-interval screening



Broadbent, Deborah M, Sampson, Christopher J, Wang, Amu, Howard, Lola, Williams, Abigail E, Howlin, Susan U, Appelbe, Duncan, Moitt, Tracy ORCID: 0000-0002-5579-996X, Cheyne, Christopher P, Rahni, Mehrdad Mobayen
et al (show 6 more authors) (2019) Individualised screening for diabetic retinopathy: the ISDR study - rationale, design and methodology for a randomised controlled trial comparing annual and individualised risk-based variable-interval screening. BMJ OPEN, 9 (6). e025788-.

[img] Text
e025788.full.pdf - Published version

Download (717kB) | Preview

Abstract

<h4>Introduction</h4>Currently, all people with diabetes (PWD) aged 12 years and over in the UK are invited for screening for diabetic retinopathy (DR) annually. Resources are not increasing despite a 5% increase in the numbers of PWD nationwide each year. We describe the rationale, design and methodology for a randomised controlled trial (RCT) evaluating the safety, acceptability and cost-effectiveness of personalised variable-interval risk-based screening for DR. This is the first randomised trial of personalised screening for DR and the largest ophthalmic RCT in the UK.<h4>Methods and analysis</h4>PWD attending seven screening clinics in the Liverpool Diabetic Eye Screening Programme were recruited into a single site RCT with a 1:1 allocation to individualised risk-based variable-interval or annual screening intervals. A risk calculation engine developed for the trial estimates the probability that an individual will develop referable disease (screen positive DR) within the next 6, 12 or 24 months using demographic, retinopathy and systemic risk factor data from primary care and screening programme records. Dynamic, secure, real-time data connections have been developed. The primary outcome is attendance for follow-up screening. We will test for equivalence in attendance rates between the two arms. Secondary outcomes are rates and severity of DR, visual outcomes, cost-effectiveness and health-related quality of life. The required sample size was 4460 PWD. Recruitment is complete, and the trial is in follow-up.<h4>Ethics and dissemination</h4>Ethical approval was obtained from National Research Ethics Service Committee North West - Preston, reference 14/NW/0034. Results will be presented at international meetings and published in peer-reviewed journals. This pragmatic RCT will inform screening policy in the UK and elsewhere.<h4>Trial registration number</h4>ISRCTN87561257; Pre-results.

Item Type: Article
Uncontrolled Keywords: ISDR Study Group, Humans, Diabetic Retinopathy, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Disease Progression, Probability, Risk Assessment, Ophthalmology, Quality of Life, Health Policy, Cost-Benefit Analysis, Workload, Referral and Consultation, Randomized Controlled Trials as Topic, United Kingdom
Depositing User: Symplectic Admin
Date Deposited: 18 Jun 2019 13:22
Last Modified: 19 Jan 2023 00:39
DOI: 10.1136/bmjopen-2018-025788
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3046407